These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 19032118)

  • 1. Importance of circadian rhythmicity in the cholinergic treatment of Alzheimer's disease: focus on galantamine*.
    Nieoullon A; Bentué-Ferrer D; Bordet R; Tsolaki M; Förstl H
    Curr Med Res Opin; 2008 Dec; 24(12):3357-67. PubMed ID: 19032118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circadian cholinergic rhythms: implications for cholinesterase inhibitor therapy.
    Davis B; Sadik K
    Dement Geriatr Cogn Disord; 2006; 21(2):120-9. PubMed ID: 16391473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cholinergic system, circadian rhythmicity, and time memory.
    Hut RA; Van der Zee EA
    Behav Brain Res; 2011 Aug; 221(2):466-80. PubMed ID: 21115064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease.
    Cooke JR; Loredo JS; Liu L; Marler M; Corey-Bloom J; Fiorentino L; Harrison T; Ancoli-Israel S
    Drugs Aging; 2006; 23(6):503-11. PubMed ID: 16872233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of Galantamine on sleep quality in Thai Alzheimer's disease patients.
    Chankrachang S; Senanarong V; Poungvarin N; Phanthumchinda K; Tavichachart N; Praditsuwan R; Nidhinandana S
    J Med Assoc Thai; 2008 Sep; 91(9):1343-9. PubMed ID: 18843862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotinic cholinergic modulation: galantamine as a prototype.
    Woodruff-Pak DS; Lander C; Geerts H
    CNS Drug Rev; 2002; 8(4):405-26. PubMed ID: 12481195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.
    Blesa R; Davidson M; Kurz A; Reichman W; van Baelen B; Schwalen S
    Dement Geriatr Cogn Disord; 2003; 15(2):79-87. PubMed ID: 12566596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Galantamine: a novel cholinergic agent for Alzheimer's disease].
    Olazarán J; García G
    Neurologia; 2002 Oct; 17(8):429-36. PubMed ID: 12396973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scopolamine does not impact declarative and motor memory consolidation across a night of sleep or a day of wakefulness.
    Tucker MA; Taylor K; Merchant R; George S; Stoddard C; Kopera K
    Neurobiol Learn Mem; 2018 Nov; 155():371-378. PubMed ID: 30172950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
    Imbimbo BP
    CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status and new developments with galantamine in the treatment of Alzheimer's disease.
    Tariot P
    Expert Opin Pharmacother; 2001 Dec; 2(12):2027-49. PubMed ID: 11825333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galantamine for vascular cognitive impairment.
    Birks J; Craig D
    Cochrane Database Syst Rev; 2006 Jan; (4):CD004746. PubMed ID: 23862185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on Alzheimer drugs (galantamine).
    Raskind MA
    Neurologist; 2003 Sep; 9(5):235-40. PubMed ID: 12971834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galantamine for Alzheimer's disease.
    Prvulovic D; Hampel H; Pantel J
    Expert Opin Drug Metab Toxicol; 2010 Mar; 6(3):345-54. PubMed ID: 20113148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease.
    Maelicke A
    Dement Geriatr Cogn Disord; 2000 Sep; 11 Suppl 1():11-8. PubMed ID: 10971047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circadian rhythm in Alzheimer disease after trazodone use.
    Grippe TC; Gonçalves BS; Louzada LL; Quintas JL; Naves JO; Camargos EF; Nóbrega OT
    Chronobiol Int; 2015; 32(9):1311-4. PubMed ID: 26376345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute cholinergic syndrome in a patient with Alzheimer's disease taking the prescribed dose of galantamine.
    Hanazawa T; Kamijo Y; Yoshizawa T; Fujita Y; Usui K; Haga Y
    Psychogeriatrics; 2018 Sep; 18(5):434-435. PubMed ID: 29993163
    [No Abstract]   [Full Text] [Related]  

  • 20. Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease.
    Stahl SM; Markowitz JS; Papadopoulos G; Sadik K
    Curr Med Res Opin; 2004 Apr; 20(4):517-24. PubMed ID: 15119989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.